The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience

BACKGROUND: Genomic tests are increasingly being used by clinicians when considering adjuvant chemotherapy for patients with oestrogen receptor-positive (ER+), human epidermal growth factor 2-negative (HER2−) breast cancer. The Oncotype DX breast recurrence score assay was the first test available i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Breast Cancer Res Treat
Päätekijät: Crolley, Valerie E., Marashi, Husam, Rawther, Shabbir, Sirohi, Bhawna, Parton, Marina, Graham, Janine, Vinayan, Anup, Sutherland, Stephanie, Rigg, Anne, Wadhawan, Anshu, Harper-Wynne, Catherine, Spurrell, Emma, Bond, Hannah, Raja, Fharat, King, Judy
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2020
Aiheet:
Epidemiology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7103011/
https://ncbi.nlm.nih.gov/pubmed/32170635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05578-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia